Anti-LOX 1 antibody [23C11],Abcam,AB81709
ab81709 neutralizes the biological activity of LOX 1. It also inhibits Hsp70 binding to dendritic cells and Hsp70 induced antigen cross representation. In vivo , targeting LOX1 with a tumor antigen using anti LOX 1 antibody ab81709 induces anti tumor immunity.
Host
Mouse
Reactivity
Human
Application
IHC-P, Flow Cyt
Platform ID
BAB998377544

Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.. (Microbial infection) May serve as a receptor for adhesin A variant 3 (nadA) of N.meningitidis. See full target information OLR1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
Please provide the required information below so that we can quickly source your products.
